Abstracts tagged "Lung Disease"

Abstract Number: 412 • 2013 ACR/ARHP Annual Meeting
Clinical Characterization Of Extensive Interstitial Lung Disease In Rheumatoid Arthritis Patients
Masaomi Yamasaki, Rheumatology, Shin-Yokohama Yamasaki Clinic, Yokohama, Japan

Background/Purpose: To investigate clinical characteristics of interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients, and to analyze whether high resolutional CT (HRCT) can predict…
Abstract Number: 2574 • 2013 ACR/ARHP Annual Meeting
Early Use of Prostacyclin Therapy Improves Transplant-Free Survival in Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension Plus Interstitial Lung Disease
Elizabeth Volkmann¹, Rajan Saggar², Bryant Torres¹, Lynne Yoder², Robert Elashoff³, Rajeev Saggar⁴, Harsh Agrawal¹, Nabeel Borazan⁵, Sarah Thomas¹ and Daniel Furst¹, ¹Medicine, University of California, Los Angeles, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Biomath, University of California, Los Angeles, Los Angeles, CA, ⁴Critical Care Medicine, St. Joseph's Hospital and Medical Center, Phoenix, AZ, ⁵Medicine, Rheumatology UCLA, Los Angeles, CA
Background/Purpose: The leading causes of death in systemic sclerosis (SSc) are pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). Use of PAH therapy in…
Abstract Number: 2567 • 2013 ACR/ARHP Annual Meeting
Cadherin-11 Regulates Pulmonary Fibrosis In Bleomycin-Induced Lung Injury
Mesias Pedroza, Anuh T. George and Sandeep K. Agarwal, Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX
Background/Purpose: Pulmonary fibrosis (PF) is the leading cause of death in systemic sclerosis. Pathologically, PF is characterized by an aberrant wound healing repair mechanism leading…
Abstract Number: 2070 • 2013 ACR/ARHP Annual Meeting
Cytokine Profiles In Polymyositis and Dermatomyositis Complicated With Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Interstitial Lung Disease Or Anti-Aminoacyl tRNA Synthetase Antibody-Associated Interstitial Lung Disease
Takahisa Gono, Yasushi Kawaguchi, Hirotaka Kaneko, Yasuhiro Katsumata, Masanori Hanaoka, Sayuri Kataoka, Hidenaga Kawasumi, Kae Takagi, Hisae Ichida, Sayumi Baba, Yuko Okamoto, Yuko Ota and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Polymyositis (PM) / dermatomyositis (DM) are often complicated with interstitial lung disease (ILD). In PM/DM, complication with ILD is associated with anti-aminoacyl-tRNA synthetase (ARS),…
Abstract Number: 2076 • 2013 ACR/ARHP Annual Meeting
Oxidation Products Of Arachidonic Acid and Linoleic Acid Are Increased In High Density Lipoprotein From Patients With Dermatomyositis and Polymyositis
Christina Charles-Schoeman¹, Yuen Yin Lee¹, Ani Shahbazian¹, David Meriwether², Geraldine Navarro¹, John D. FitzGerald¹ and Srinivasa T. Reddy², ¹Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Medicine-Cardiology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Oxidation products of arachidonic acid and linoleic acid including hydroxyeicosatetraenoic acids (HETEs) and hydroxyoctadecadienoic acids (HODEs), respectively, play an important role in the…
Abstract Number: 2077 • 2013 ACR/ARHP Annual Meeting
Inflammatory Lung Disease a Potential Risk Factor For Onset Of Inflammatory Myopathies
Ingrid E. Lundberg¹, Sevim Barbasso Helmers² and Lars Alfredsson³, ¹Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²Institute of Environmental Medicine, Unit of Cardiovascular Epidemiology, Karolinska Institutet, Stockholm, Sweden, ³Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Although the etiology of inflammatory myopathies is unclear, there are data indicating that myositis occurs as a result of complex interactions between genes and…
Abstract Number: 2079 • 2013 ACR/ARHP Annual Meeting
Serum Interferon α, β and Interleukin-18 Are Associated With Disease Activity Of Rapidly Progressive Interstitial Lung Disease In Patients With Clinical Amyopathic Dermatomyositis
Shinji Sato¹, Noriko Sasaki¹, Shinichi Nogi¹, Naofumi Chinen², Kiri Honda¹, Eiko Saito¹, Chiho Yamada² and Yasuo Suzuki², ¹Rheumatology, Tokai University School of Medicine, Isehara, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: It is well known that rapidly progressive interstitial lung disease (RP-ILD) in patients with dermatomyositis (DM) is associated with poor outcome. Previous findings suggested…
Abstract Number: 2053 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Intermittent Intra-Venous Cyclophosphamide and Cyclosporin A Combination Therapy For Rapidly Progressive Interstitial Lung Disease With Dermatomyositis Associated With Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody Titer
Noriko Sasaki¹, Shinji Sato¹, Shinichi Nogi¹, Naofumi Chinen², Kiri Honda¹, Eiko Saito¹, Chiho Yamada² and Yasuo Suzuki², ¹Rheumatology, Tokai University School of Medicine, Isehara, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) autoantibody is present specifically in patients with dermatomyositis (DM), especially those with few or no muscle manifestations (clinically amyopathic…
Abstract Number: 922 • 2013 ACR/ARHP Annual Meeting
Role Of B Cells and/Or Autoantibodies In Pulmonary Manifestations Of Inflammatory Arthritis
Lisa K. Peterson¹, Jeremy Sokolove², Paul Jedlicka³, Lauren J. Lahey⁴, William H. Robinson⁵ and Leonard L. Dragone⁶, ¹Pediatrics, National Jewish Health, Denver, CO, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ³Pathology, University of Colorado Denver, Aurora, CO, ⁴Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁵VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁶Dept of Pediatrics, National Jewish Health, Denver, CO
Background/Purpose: RA is a systemic condition affecting approximately 1% of the general population leading to progressive arthritis and extra-articular manifestations (ExRA), including interstitial lung disease…
Abstract Number: 926 • 2013 ACR/ARHP Annual Meeting
Autoantibodies to the Th/To Complex Are the Most Common Antibodies in Systemic Sclerosis (SSc) Patients Without Other Autoantibodies
Michael Mahler¹, Jason Y.F. Chan², Edward K.L. Chan³, Minoru Satoh², Marie Hudson⁴, Murray Baron⁵, James Wick⁶ and Marvin J. Fritzler⁷, ¹Research, INOVA Diagnostics, San Diego, CA, ²Medicine, University of Florida, Gainesville, FL, ³Oral Biology, University of Florida, Gainesville, FL, ⁴Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁵Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁶Department of medicine, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, ⁷Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Antinuclear antibodies (ANA) play an important role in the diagnosis of systemic sclerosis (SSc) being present in about 80-90% of the patients. In the…
Abstract Number: 697 • 2013 ACR/ARHP Annual Meeting
Longitudinal Assessment Of Pulmonary Function In 304 Norwegian Patients With Systemic Sclerosis
Anna-Maria Hoffmann-Vold¹, Torhild Garen², Oyvind Midtvedt¹, May-Brit Lund³, Jan Tore Gran¹ and Øyvind Molberg⁴, ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Pulmonary Unit, Oslo University Hospital, Rikshopitalet, Oslo, Norway, ⁴Oslo University Hospital, Oslo, Norway
Background/Purpose: The purpose of this study was to asses sequential pulmonary function measurements (forced vital capacity [FVC] % predicted) in a large systemic sclerosis (SSc)…
Abstract Number: 666 • 2013 ACR/ARHP Annual Meeting
Involvement Of TCR Vdelta1⁺ NKT Cells In Systemic Sclerosis: Association With Interstitial Pneumonia
Seiji Segawa¹, Daisuke Goto², Masanobu Horikoshi², Yuya Kondo³, Naoto Umeda², Shinya Hagiwara², Masahiro Yokosawa⁴, Tomoya Hirota³, Haruka Miki¹, Hiroto Tsuboi³, Hiroshi Ogishima², Takeshi Suzuki⁴, Isao Matsumoto⁵ and Takayuki Sumida³, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan, ²Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba City, Japan, ³Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁴Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, ⁵Department of Internal Medicine, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Interstitial pneumonia (IP) is one of the critical complications in patients with several autoimmune diseases. However, the exact mechanism of IP remains elusive. Recently,…
Abstract Number: 675 • 2013 ACR/ARHP Annual Meeting
Impact Of Male Sex On Survival In Systemic Sclerosis
Haseena Hussein¹, Peter Lee², Cathy Chau³ and Sindhu R. Johnson⁴, ¹Medicine, Toronto Scleroderma Research Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, ³Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) has a female predominance with a female-to-male ratio of 3:1. Sex differences have been seen in many autoimmune diseases; however, little…
Abstract Number: 648 • 2013 ACR/ARHP Annual Meeting
A Possible Contribution of Inducible Costimulator to the Development of Skin Sclerosis and Interstitial Lung Disease in Systemic Sclerosis
Koichi Yanaba¹, Yoshihide Asano² and Shinichi Sato², ¹Dermatology, The University of Tokyo, Tokyo, Japan, ²Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous disorder characterized by excessive fibrosis and microvascular damage of the skin and various internal organs. Cutaneous mononuclear cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].